首頁 › 伯基特淋巴瘤 › 紐約州 › New York City
New York City, NY 的 伯基特淋巴瘤 臨床試驗
13 項針對 伯基特淋巴瘤 的研究正在 New York City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
招募中3 期
- Memorial Sloan Kettering Cancer Center, New York
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- 還有 1 項
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
招募中3 期
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- David H. Koch Center for Cancer Care, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- 還有 2 項
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
招募中1/2 期
- Research Site, New York
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
招募中2 期
- Memorial Sloan Kettering Cancer Center, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- Weill Cornell, New York
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
招募中1/2 期
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
其他城市的 伯基特淋巴瘤 試驗
- Houston, TX21 項研究
- Philadelphia, PA16 項研究
- Milwaukee, WI16 項研究
- Chicago, IL15 項研究
- Cincinnati, OH13 項研究
- Atlanta, GA12 項研究
- Aurora, CO11 項研究
- Seattle, WA11 項研究
- Durham, NC10 項研究
- Boston, MA10 項研究
- Kansas City, MO10 項研究
- Los Angeles, CA10 項研究
New York City 的其他研究
- 乳癌136 項研究
- 非小細胞肺癌121 項研究
- 癌症（所有類型）109 項研究
- 前列腺癌103 項研究
- 轉移性癌症93 項研究
- 大腸直腸癌78 項研究
- 卵巢癌69 項研究
- 肺癌60 項研究
- 多發性骨髓瘤60 項研究
- 胰臟癌60 項研究
- 子宮內膜癌52 項研究
- 急性髓系白血病51 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。